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Current status of defensins and their role
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School of Dentistry, Marquette University, Milwaukee, WI

Abstract

Naturally occurring antimicrobial cationic polypeptides play a major role in innate and adaptive
immunity. These polypeptides are found to be either linear and unstructured or structured
through disulfide bonds. Among the structured antimicrobial polypeptides, defensins comprise
a family of cysteine-rich cationic polypeptides that contribute significantly to host defense
against the invasion of microorganisms in animals, humans, insects and plants. Their widespread occurrence in various tissues of these diverse organisms, and their importance in innate
and adaptive immunity have led to their identification, isolation and characterization. A large
volume of literature is available on defensins’ occurrence, structural characterization, gene
expression and regulation under normal and pathological conditions. Much has also been
published regarding their antimicrobial, antiviral and chemoattractive properties, and their
molecular and cellular interactions. In this review, we describe the current status of our
knowledge of defensins with respect to their molecular, cellular and structural biology, their
role in host defense, future research paradigms and the possibility of their utilization as a new
class of non-toxic antimicrobial agents and immuno-modulators.
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Introduction

Antimicrobial peptides are widely distributed in nature and represent an ancient mechanism of
host defense. Among these naturally occurring antibiotic peptides, defensins form a unique
family of cysteine-rich cationic and structured polypeptides with three or four disulfide bridges.
Defensins are isolated from mammals, insects, and plants and they serve as effector molecules
of innate immunity, providing an efficient initial defense against infectious pathogens.1,2
Mammalian and other vertebrate defensins are quite different from the arthropod defensins in
their sequence and structure.3,4 Mammalian defensins comprise genetically distinct α- and β-

subfamilies of cationic tri-disulfide peptides. Most defensins appear to be expressed
constitutively, whereas mediators of inflammation induce the biosynthesis of others.5
Defensins exhibit remarkable antibacterial, antifungal and antiviral activities against a wide
variety of microorganisms,1,5 suggesting their role in innate immunity. They also play a major
role in adaptive immunity.6 It is now becoming clear that defensins constitute a primary
defense system of the host. The activity of a few α-defensins as specific antagonists of
adrenocorticotropin has led to their classification as the corticostatin/defensin family.7 This
review focuses on the current status of defensins in terms of their wide-spread occurrence,
their molecular, cellular and structural biology, structure–function relationships, mechanism of
their microbicidal activity and future research paradigms.

Occurrence, isolation, identification and classification

Defensins were first identified as a family of peptides in rabbit macrophages and subsequently
in rabbit, rat, human and guinea-pig neutrophils, and they all belong to the α-defensin subclass.2,8 Their primary structures, the sequence homology, the conserved cysteine residues and
the disulfide linkages of representative α-defensins are provided in Fig. 1. α-Defensins are
found in neutrophils of humans, rabbits, guinea pigs, rats, macaques and hamsters, in rabbit
alveolar macrophages and in human and rodent small intestinal Paneth cells.8 β-Defensins were
originally isolated as a family of 13 homologous peptides in bovine neutrophils.9 The folding of
the peptide chains and the disulfide motifs (Fig. 2) are distinctly different from α-defensins9
Subsequently, β-defensins were reported to be expressed in skin, pancreas, kidney, salivary
glands, prostate, placenta, endocervix, and airway and gingival epithelial cells of
vertebrates.10,12 α-Defensins consist of 29–35 amino acid residues and are shorter than βdefensins, consisting of 38–42 residues. α- and β-defensins differ in the location and position of
the cysteine residues in the amino acid sequence and in their disulfide motifs. Two human βdefensins, HBD-1 and HBD-2, were structurally characterized and their presence in human skin,
plasma, saliva, and in the urogenital tract have been identified.12,14 HBD-3 has been identified
and its expression in adult heart, skeletal muscle, placenta, skin, esophagus, gingival
keratinocytes, trachea and fetal thymus detected.15 A new and novel HBD-4 has recently been
identified and its tissue-specific inducible and restricted expression in the testis, uterus, thyroid
gland, lung and kidney during infection reported.16

Amino acid sequences of α-defensins in human neutrophils (HNP), human intestinal Paneth cells (HD),
rabbit neutrophils (NP) and rabbit kidney (RK). In HNP sequences, the different amino terminal residue is
underlined. The conserved disulfide bridges in α-defensins are indicated in HNP-4. The conserved residues
within a species are bold and underlined.

Amino acid sequences of β-defensins in human and bovine neutrophils (HBD and BNBD, respectively),
and two Mediterranean mussel defensins (MGD). The conserved disulfide bridges in β-defensins are
indicated in HBD-3. The conserved residues in human and bovine neutrophil β-defensins are bold and
underlined. In Mediterranean mussel defensins, the residues that are not conserved are underlined. The
disulfide motifs of various defensins are provided in the figure. pE: pyroglutamic acid.

Several defensins isolated from arthropods have been found to display interesting sequence
homology to defensins isolated from Mediterranean mussels, even though they belong to
markedly distinct phylogenetic groups.17 However, these polypeptides differ distinctly (Fig. 2)
from mammalian and other vertebrate defensins. Though three disulfide bonds generally
characterize defensins, a few insect defensins with four disulfide bridges have been isolated
from Mytilus galloprovincialis.17 Defensins isolated from a variety of plants display high
sequence identity with each other and their amphiphilic β-sheet structure resembles that of
animal defensins shown in Fig. 3.18 Plant defensins with four disulfide linkages at highly
conserved locations are designated as γ-thionins. Even though defensins with four disulfide
bridges have been isolated and characterized from insects and plants, such defensins have not
yet been identified in vertebrates. Most defensins are primarily linear polypeptides, folded and

stabilized by three to four disulfide bonds. However, a defensin with the amino and carboxy
terminals cyclized by a peptide bond has been recently isolated from primate leukocytes.19

A perspective view of the three-dimensional basket-like amphiphilic structure of NP defensin human
neutrophil-3 deduced from the crystal structure [31]. The side-chains are not included for clarity. The
yellow color indicates the disulfide bridge. The N- and C-terminal residues form the polar face at the top,
whereas the middle region assumes the apolar face (the lower portion) of the amphiphilic structure.
Differences in the sequence and in the folding pattern of mammalian, insect and plant defensins result
primarily in the alteration of polarity and hydrophobicity of the polar and apolar faces, respectively,
leading to variation in the amphiphilicity of the structure. This amphiphilicity variation reflects in
defensins’ diversity in specificity and microbicidal potency.

Gene expression, regulation and biosynthesis

Increasing evidence suggests that human α- and β-defensins might descend from a shared
ancestral gene. The genes encoding HBD-1 and HBD-2 have been assigned to human
chromosome region 8p23 and 8p22-8p23.1, respectively, close to the α-defensins.12 The 5′flanking region of HBD-1 contains nuclear factor (NF)-interleukin (IL)-6 and γ-interferon
consensus sites, suggesting that inflammatory mediators could regulate its expression.14 The
cDNA and genomic sequences of the two rabbit macrophage defensins are highly homologous
and identical to rabbit neutrophil defensins NP1 and NP2, respectively. These genes are closely
linked within 13 kb, suggesting that they evolved by a recent tandem gene duplication. The
rabbit macrophage defensin mRNA is found in bone marrow and spleen and organs that
contain immature polymorphonuclear leukocytes (PMNs).20 While matured PMNs lack defensin
mRNA, the possibility of a certain degree of mRNA and protein synthesis in activated PMNs has
not yet been ruled out.

α-Defensins are produced and stored as pre-propeptides in matured PMNs and Paneth cells. βDefensins are constitutively expressed in the epithelial compartment and can be induced to
higher levels of expression upon infection or inflammation. Metabolic labeling studies in the
promyelocytic cell line HL-60 and in chronic myeloid leukemia cells indicate that human
neutrophil pre-prodefensins are processed to mature defensins over 4–24 h via a 75-residue
prodefensin generated by the cleavage of the signal sequence and a 56-residue prodefensin
resulting from a subsequent proteolytic cleavage.11 The post-translational and enzymatic
processing of pre-prodefensins to mature peptides with storage in cytoplasmic granules is a
specialized feature of granulocytic lineage cells.12 The α-defensins in Paneth cells are also
synthesized as pre-prodefensins, but they are secreted into the lumen of the small intestine
where they are proteolytically cleaved into active antimicrobial peptides. The expression of
human Paneth cell defensins HD-5 and HD-6 is found to be minimal in oral keratinocytes,
whereas HD-5 mRNA is expressed infrequently and to varying degrees in bronchial and nasal
epithelial cells.21 The expression of human α- and β-defensin mRNA in gastrointestinal epithelia
has been found to be tissue- and peptide-specific, and the defensins are expressed with high
inter-individual variability. Cloning and expression of bovine neutrophil β-defensins indicate
that the precursor structures of α- and β-defensins are quite different. The structural
differences of the two defensin families suggest that they could be stored and packaged by
distinct intracellular pathways and mobilized differently from the respective cells.
β-Defensins are essentially synthesized in the epithelial compartment with the exception of
bovine neutrophils. In epithelial cells, HBD genes are found to be both constitutively expressed
and inducible. Gene expression has been shown to be induced in vitro by stimulation with
bacterial lipopolysaccharide (LPS) as well as inflammatory mediators. In vivo, up-regulation of
β-defensin genes has been shown to occur in both infectious and inflammatory states. Gene
regulation appears to proceed via signal-transduction pathways utilizing NFs including NF-κB
and NF-IL-6. The amino acid L-isoleucine and several of its analogs can specifically induce
epithelial β-defensin expression involving the activation of the NF-κB/rel family of transactivating factors, suggesting that isoleucine analogs may serve as immuno-stimulants to
bolster the defense barrier of mucosal surfaces.22
Characterization and transcriptional profiles of a Drosophila gene encoding an insect defensin
suggest that insect and mammalian defensins might have evolved independently.23 Though it is
commonly believed that insect defensin gene expression is only induced upon septic injury and
infection, the constitutive expression of defensin peptides in insects has recently been
observed. These results suggest two modes of defense against infection in insects. The first one
is the transcription of the genes encoding defensin-like peptides, mainly in the fat body after
septic injury, with a rapid release of the peptides into the hemolymph, and the second mode is
the constitutive production and storage of the defensin peptides, particularly in hemocytes
with subsequent release into the hemolymph after immune challenge.
Plant defensins also form part of the permanent and inducible defense barriers. In plants, both
small and large cysteine-rich defensin genes are induced through different signal-transduction
pathways during fruit ripening to protect the reproductive organs against biotic and abiotic

stress.14 These data suggest that defensins are constitutively and inducibly expressed across the
phylogenetic spectrum.

Defensins – key components of innate and adaptive immunity

The presence of defensins in lower organisms clearly indicates their ancient origins, and argues
that they developed as a part of a primordial immune protective mechanism. Defensins exhibit
broad-spectrum antimicrobial activity against bacteria, fungi, mycobacteria and enveloped
viruses. Constitutive expression of defensins provides a first line of defense against colonization
by pathogens. Normal gingival epithelial cells express β-defensins, indicating their importance
in host–pathogen interaction at the oral mucosal barrier and their relevance in oral health. The
deficiency of neutrophil defensins has been associated with the risk for invasive bacterial
infections observed in the newborn. Mucoid Pseudomonas aeruginosa, tumor necrosis factor
(TNF)-α and IL-1β, but not IL-6, induce HBD-2 expression in respiratory epithelia, suggesting the
protective role of HBD-2 in lung infection caused by mucoid P. aeruginosa. Defensins can also
activate the classical complement pathway, and they have the potential to modify the
inflammatory response through the regulation of cytokine production and adhesion-molecule
expression.24 All these observations suggest a key role for defensins in innate immunity.
Evidence is accumulating to support the role of defensins in the activation and in the
recruitment of the cells and machinery of the adaptive immune response. Defensins provide a
critical link between the innate immune system, which is phylogenetically ancient, and the
adaptive immune response that is found only in vertebrates. The innate immune system relies
on germline-encoded receptors on epithelial cells and phagocytes as sentinels of the host–
environment boundary. These pattern-recognition receptors (PRRs) recognize conserved
pathogen-associated molecular patterns (PAMPs) such as LPS, peptidoglycan, zymosan and
possibly isoleucine.22 These PRRs initiate an appropriate antimicrobial response to try to
contain infection, which involves the up-regulation of specific antimicrobial peptides including
defensins. The second major task for the innate immune system is to activate an appropriate
adaptive immune response against the invading organism. Recent data suggests that defensins
may play a key role in the recruitment and activation of the appropriate adaptive effector
response.25 Examples of the stimulatory effects of defensins on humoral and cell-mediated
immune elements illustrate this connection.22,25
Human α-defensins are chemotactic to monocytes, dendritic and T-cells at ∼10−10 M
concentration, suggesting their importance in shaping the adaptive immune response. βDefensins are chemotactic for dendritic and memory T-cells through the chemokine receptor
CCR6.19 In a murine model, human neutrophil defensins delivered intra-nasally with ovalbumin
have been shown to enhance the systemic adaptive immune response by increasing antigenspecific IgG and IgM levels in serum.26 β-Defensin gene expression in vertebrate epithelia,
including that of humans, and their up-regulation in the presence of bacterial LPS and TNF-α
emphasize that these molecules might function to protect the host against microbial
pathogenesis at the critical confrontation sites. These studies provide convincing evidence that
defensins play a key role in directing and augmenting an adaptive immune response.

Defensins as antimicrobial and antiviral agents

Defensins exhibit remarkable antibacterial, antifungal and antiviral activity against a wide
variety of microorganisms, as established by in vitro studies.2,8 The in vitro minimal inhibitory
concentrations against a panel of microorganisms range between ∼0.5 and 10 μM for most
defensin peptides.8 In vitro studies, however, do not mimic the in vivo environment, where
inflammatory exudates, phagosomes, ions, serum factors and proteases might alter the efficacy
of these peptides. Hence, the microbicidal efficacy observed for defensins cannot be directly
related to in vivo applications. However, defensin concentration in vivo might reach significant
levels at the site of production and secretion (5 μg/10−6 human granulocytes). Neutrophil
defensin concentration has been elevated by 500–10 000 fold in bronchoalveolar lavage of
cystic fibrosis (CF) individuals. The concentration of human neutrophil peptide (HNP-1) in the
saliva of patients with oral diseases and oral inflammation are found to be significantly higher
than those in healthy subjects.27 The local concentration of defensins has been estimated to be
in the mg ml−1range in human gingival crevicular fluid. These observations suggest that
defensins are present in vivo in significant amounts that are likely to have major effects on the
microbiology of the host. In addition to their high concentration, the microbicidal activity of
defensins in vivo could be enhanced due to the synergistic interaction with other proteins such
as lactoferrin and cathelicidins. Defensin and lactoferrin levels are found to be elevated in the
cerebrospinal fluid of children with meningitis.8 The synergistic action of defensins with other
host-protective proteins is likely to be relevant in the host–pathogen interaction in vivo.
Defensins exhibit remarkable antiviral activity against recombinant adeno-associated virus and
Herpes simplex virus. Direct binding of defensins appears to prevent envelope virus
infectivity.1,28

Mechanism of antimicrobial activity

The antibacterial activity of defensins is generally ascribed to their effects on microbial
membranes. Defensin-like peptides, being positively charged, interact with negatively charged
components of microbial membranes that include LPS in Gram-negative bacteria,
polysaccharides (teichoic acid) in Gram-positive bacteria, and phospholipids (phosphotidylglycerol). Since these membrane components are PAMPs that are not found in mammalian
cells, defensins in general appear to be electrostatically specific for prokaryotic cells [5]. Human
defensin HNP-1 has been shown to mediate bactericidal activity against Escherichia coli by
permeabilizing the outer and inner membranes. An insect defensin with β-sheet structure has
been reported to permeabilize the cytoplasmic membrane of Micrococcus luteus. Defensins
in M. luteus cells cause depolarization of cytoplasmic membrane, inhibition of respiration, and
loss of cytoplasmic potassium and ATP, suggesting that defensins target the bacterial
cytoplasmic membrane. All research regarding modes of action of antibiotic peptides has been
carried out with lipid model planar bilayer membranes or small unilamellar vesicles formed
from lipid mixtures of various compositions of negatively charged to neutral lipids.5,8 These
studies have led to the hypothesis that in Gram-positive bacteria, the monomeric peptides
aggregate to form multimeric pores in the cell's single cytoplasmic membrane. In the case of
Gram-negative bacteria, defensins have to traverse the outer membrane. The high affinity of
defensins for LPS facilitates competitive displacement of divalent cations (Ca2+ or Mg2+) that

serve as a bridge between the LPS molecules.29 The initial interaction of defensin with a target
membrane causes rapid permeabilization of the inner membrane in E. coli. A small defensin-like
dodecapeptide with a disulfide bridge permeabilizes the outer membrane of P.
aeruginosa and Salmonella typhimurium and this membrane activity appears to correlate with
its microbicidal activity. This peptide also interacts with the cytoplasmic membrane of an outer
membrane-defective mutant E. coli. However, a recent study of cationic antimicrobial peptides
of varying structures with a planar bilayer and with the cytoplasmic membrane of E.
coli suggests the possibility that the cytoplasmic membrane is not the target for some or even
most cationic antimicrobial peptides. Stimulation of autolytic enzymes, interference with
bacterial DNA and/or protein synthesis, inhibition of DNA synthesis leading to filamentation, or
binding to and inhibition of cellular nucleic acids have been suggested as the possible
mechanism of action. Interaction with cellular nucleic acids has been suggested as a credible
alternative mechanism. Increasing evidence indicates that the antimicrobial mechanism and the
cytoplasmic target could vary with the primary sequence and the amphiphilicity of the
antimicrobial peptide.30
Electrostatic interactions between defensins and the target cell membrane ruling out any
specific membrane-bound receptor could account for the rare occurrence of resistant bacterial
strains. However, specific binding sites for plant defensins on fungal cells are required for
antifungal activity. The resistant strains of S. typhimurium and Staphylococcus aureus have been
reported to have modified membrane structure involving LPS and teichoic acid, respectively,
resulting in the neutralization of electrostatic charge, thereby minimizing the interaction with
defensin peptides. These studies provide convincing evidence that defensins’ initial interaction
is with the LPS and teichoic acid of Gram-negative and Gram-positive bacteria, respectively. This
is also consistent with the role of defensins in innate immunity and a possible adjuvant role in
adaptive immunity. The emergence of resistant strains may have implication directly on the
antimicrobial activity and/or on the efficacy of defensins to activate the immune system.
Further research in this direction is required to clarify the function of defensins under these
circumstances.
Defensins are expected to be minimally active on host-cell membranes. Their selective toxicity
is associated with the anionic phospholipid of microbial membranes. In contrast, zwitterionic
phospholipids and the presence of cholesterol in mammalian cell membranes partly account for
the minimal cytotoxicity to host cells.8 However, in vitro studies indicate that human defensins
can have lytic effects on human lymphocytes and endothelial cells as well as murine lymphoid
cells. The cytolytic mechanism involves an early step of membrane binding, followed by a series
of cytoskeletal-dependent events that are sensitive to concentration, energy, and temperature.
The first stage of membrane binding in the defensin-mediated cytotoxicity is inhibited under
conditions of low temperature and by the presence of serum and heparin.8 The tolerance of
human erythrocytes, epithelial and endothelial cells to defensins at physiological
concentrations, temperature, pH and ionic strength has not yet been systematically
established. These studies would provide invaluable information for defensins’ application in
pharmaceutical industries.

Structure–function correlations

The sequence homology is more than 90% conserved for defensins isolated from a specific
tissue within a given species. For instance, human neutrophil α-defensin sequences are
conserved except for one amino acid at the N-terminus. Rabbit neutrophil defensins mostly
differ only at the C- and N-terminal residues. Similarly, bovine neutrophil β-defensin sequences
exhibit high sequence homology (Fig. 2). The size and sequence homology of defensins vary to a
greater extent when compared with those isolated from different biological sources. The
sequences of human and rabbit neutrophil defensins differ widely (Fig. 1). The minor variations
within a family of defensins affect significantly their specificity and microbicidal potency. HNP-1
is a potent antifungal agent against Candida albicans, whereas HNP-3 has minimal activity.
These two defensins differ only in one amino acid at the N-terminus (Fig. 1). Similarly, HNP-2 is
significantly less active against C. albicans as compared with HNP-1. The only difference
between these two molecules is one alanine residue at the N-terminus (Fig. 1). Interestingly,
human defensins HNP-1 and HNP-2 are equipotent in their cidal activity
against Capnocytophagaspecies, and their activity is significantly greater than that of HNP-3.
Similar variations in the bactericidal activity of rat defensins have also been observed. This wide
functional diversity observed in the family of similarly structured defensins is clearly a
consequence of minute alterations in sequence, chain length, backbone conformation and sidechain topography.
The three-dimensional structures of a few α-defensins reported in the crystalline state and in
solution4,31 indicate amphiphilic triple-stranded β-sheet structures (Fig. 3). The N- and Cterminal residues form the polar face, and the middle portion of the sequence constitutes the
apolar face of the amphiphilic structure (Fig. 3). The polar and apolar faces of the β-sheet
structure show distinct differences in the amphiphilicity of α-, β-, plant, and insect defensins.
These variations presumably account for their diversity in specificity and antimicrobial activity.
The residues at the polar face are found to alter significantly the microbicidal potency and
specificity of human neutrophil defensins.32 This was demonstrated by the observation that the
Gram-negative bacteria Actinobacillus actinomycetemcomitans and Porphyromonas
gingivalis and the Gram-positive bacteria Streptococcus gordonii and Streptococcus mutans are
insensitive to human neutrophil defensins. However, these same microbes are susceptible to
rabbit neutrophil defensins that differ significantly from human neutrophil defensins. Analogs
of human neutrophil defensins incorporating two additional cationic residues at the N- and Cterminals have been shown to exhibit high microbicidal potency against these organisms,
suggesting the importance of the N- and C-terminal residues for microbicidal activity. The
enhanced microbicidal activity observed for defensin analogs could be due to optimization of
the amphiphilicity of the structure, facilitating specific interactions with microbial
membranes.32
The structure of HBD-2 reported previously suggests that its dimeric structure is distinctly
different from human α-defensins. The higher-order octamer of HBD-2 supports an
electrostatic charge-based membrane permeabilization mechanism rather than that based on
formation of bilayer-spanning pores.33 The structure of bovine neutrophil β-defensin has been
shown to be a triple-stranded β-sheet, the β-bulge preceding the hairpin turn and the

amphiphilic character. The structural features are consistent with those of other β-defensins.
The three-dimensional structure of defensins has been used to design simple analogs that
mimic the structure of native molecules. The constructed analogs have been found to elicit
microbicidal potency comparable to that of native defensins.34 The microbicidal potency of
small molecules seem to support the electrostatic charge-based membrane permeabilization
mechanism. It appears that the amphiphilic structure of defensins stabilized by three or four
disulfide bridges is critical for membrane permeabilization and antimicrobial activity.

Defensins and infectious diseases

In vitro studies suggest that bacterial challenge causes an increase in defensin synthesis and
secretion by epithelial cells. In vivo studies also indicate elevated defensins concentration in
plasma, blood, and body fluids from patients with bacterial infection, suggesting defensins’
physiological significance in infection. Interestingly, microbial infection does not seem to be a
problem in the skin disorder, psoriasis. This could be due to the fact that psoriatic epithelium
up-regulates the expression of a cathelin-class antimicrobial peptide, designated as LL-37, and
HBD-2 as compared to that of normal skin.5 The synergistic activity of these molecules may
account for the rare occurrence of infection in this skin disorder.8
Cystic fibrosis (CF) patients (on the other hand) are highly susceptible to upper-respiratory
infection by bacterial and fungal pathogens. This is the result of a defective tracheal epithelial
cell gene product, namely, the CF trans-membrane conductance regulator that causes elevated
levels of Na+ and Cl− ions in the airway surface fluid. The high cationic concentration associated
with the airway surface fluid in CF patients appears to inactivate β-defensins, thereby
enhancing microbial colonization, leading to inflammation and tissue destruction.5,8 It appears
that only the monovalent and divalent cations inactivate defensins and not the anions. Since
defensins’ initial interaction with microorganisms involves electrostatic forces, the altered ionic
environment might compromise the initial interaction of defensins with microbial membranes.
Periodontitis is one of the most common chronic infectious diseases of humans and is a major
cause of tooth loss. This oral disease is strongly associated with the formation of a
predominantly Gram-negative anaerobic biofilm in the gingival crevice or periodontal pocket. P.
gingivalis and A. actinomycetemcomitans are the most well-documented periodontal
pathogens having multiple virulence factors that could circumvent normal host-defense
mechanisms. In healthy individuals, the secretion of β-defensins from oral epithelium and the
constant influx of neutrophil α-defensins along with other salivary defense molecules serve as
an efficient barrier against the formation of a pathogenic sub-gingival plaque or biofilm. The
disruption of this barrier can lead to the progression of periodontal disease. P. gingivalis uses a
mechanism known as chemokine paralysis to inhibit the expression of IL-8 by gingival epithelial
cells, which may indirectly decrease the defensin barrier by inhibiting neutrophil emigration.35
Bacterial DNA can also down-regulate the production of human defensins in epithelial cells.
Moreover, studies have demonstrated that P. gingivalis can survive the non-oxidative killing
mechanisms of PMNs, which may be of greater importance in the anaerobic environment of the
periodontal pocket. This finding may be in part due to the lack of microbicidal activity of human

neutrophil α-defensins against oral pathogens including P. gingivalis and A.
actinomycetemcomitans.32
Another mechanism that may be very important in the host–pathogen interaction, particularly
in the periodontium, is the direct deactivation or clearance of defensins by substances such as
dermatan sulfate and α 2-Macroglobulin. Approximately 60% of the glycosaminoglycan content
of healthy human gingiva is made of dermatan sulfate, which has recently been shown to bind
to defensins and completely neutralize their microbicidal activity.36 Similarly, defensin levels
may be decreased by activated α 2-macroglobulin. α 2-Macroglobulin is the major serum
protease inhibitor, which upon activation, will bind to defensin peptide.37 In the environment of
the periodontal pocket, bacterial tissue invasion and high levels of protease activity could cause
increased levels of activated α 2-macroglobulin. The defensin–α 2-macroglobulin interaction
may constitute an important mechanism in the host–pathogen interaction that warrants
further investigation.

Additional regulatory functions

Human α-defensins inhibit fibrinolysis by modulating tissue-type plasminogen activator and
plasminogen binding to fibrin and endothelial cells, which could have significant implications in
thrombotic pathology. In pathological conditions, defensins released in the circulation might
adhere to the endothelium and their presence in the vascular tissues could contribute to the
pathological consequences of inflammation. In vitro studies have shown that neutrophil
defensins interact with ACTH receptors, inhibiting ACTH-induced steroidogenesis. neutrophil
defensins induce histamine secretion from mast cells mediated by a G-protein-dependent
response, which is distinctly different from antigen-IgE-mediated activation.8 α-Defensins are
found to induce proteoglycan-dependent catabolism of low-density lipoprotein (LDL) by
vascular cells, leading to a new class of inflammatory apolipoprotein, suggesting that they could
possibly contribute to atherogenesis.8 They also regulate secretory leukocyte protease inhibitor
and elafin release from bronchial epithelial cells, indicating their role in the dynamic regulation
of the antiprotease secretion in the lung at the site of inflammation. Defensins increase
proliferation of epithelial cells, suggesting their involvement in wound healing.38 These
important biological functions establish that defensins are multifunctional cell-effector
molecules in addition to their role in integrating the innate and adaptive immune responses.

Future paradigms and summary

Increasing evidence unambiguously establishes that defensins play a major role in adaptive and
innate immunity. However, less research has been focused on the pharmaceutical application
of defensins as an alternative to circumvent microbial adaptive resistance and toxicity
associated with conventional antibiotics. Though defensins have been suggested as therapeutic
agents for several infectious diseases, the development has been hampered by difficulties and
the expenses involved in their large-scale production. However, large-scale synthesis of human
neutrophil defensins and their analogs has recently been reported.32 Recombinant technology
for the production of defensins is yet to emerge, though there are a few reports that describe
the synthesis of small amounts of defensins. Interestingly, it has been demonstrated that
defensin gene transformation and its expression impart disease resistance in plants, which is

equivalent to the conventional fumigation practice. Similar research in humans will be
invaluable to control or prevent infectious and inflammatory diseases. The toxicity of naturally
occurring defensins to human cells at physiological conditions has to be thoroughly examined
for pharmaceutical applications.
The studies on the structural biology of defensins have identified simple amphiphilic molecules
that mimic the structure of defensins and elicit similar antimicrobial potency.34 Peptide
detergents can be generated by alteration of amphiphilicity of these simple molecules. These
detergents could selectively lyse microbial membranes and target infectious pathogens. As
mentioned earlier, high ionic strength of the airway fluid associated with CF leads to the
impairment of β-defensins’ activity. However, a cyclic defensin, wherein amino and carboxy
terminals are cyclized by a peptide bond, has been reported to be active even at high ionic
strength.19 This suggests a novel approach to overcome the salt-sensitive deactivation of
defensins in CF patients. Research should focus on this class of cyclic defensins for
pharmaceutical applications when the natural defense barrier is compromised in a pathological
state. Structure–function studies could identify the functional domain for defensins’
chemotactic activity to monocytes and other adaptive immune cells. Such studies might
facilitate the design and synthesis of simple molecules that could activate or direct the adaptive
immune response, and serve as immuno-modulators.
The interaction between activated α 2-macroglobulin and defensin peptides is an undeveloped
area that warrants further investigation. With the observations that α 2-macroglobulin
functions as an extra-cellular chaperone as well as a major serum protease inhibitor, the
interplay between defensins and α 2-macroglobulin becomes more intriguing. Defensins appear
to be recycled in vivo by activated α 2-macroglobulin via receptor-mediated endocytosis.
Recycling may occur through either the LDL receptor-related protein, or CD91, the heat shock
protein receptor. Since CD91 plays a role in antigen presentation, and α 2-macroglobulin acts as
a T-cell adjuvant, one could speculate that defensins might aid in the delivery of non-self
lipoprotein or glycolipid antigens and help direct the adaptive immune response accordingly.
Further research in this area might clarify the precise role of α 2-macroglobulin in the activity of
defensins.
In summary, this review has attempted to describe the current status of defensins as natural
barriers at the host–microbe interface, linking adaptive and innate immunity. The current
knowledge of defensins envisages the possibility of their utilization as a new class of natural
antibiotics to overcome microbial adaptive resistance to existing conventional antibiotics. They
might serve as immuno-modulators to activate the immune system suppressed by infection and
inflammation.
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